J
Jennifer Clay Cather
Researcher at Baylor University Medical Center
Publications - 74
Citations - 2789
Jennifer Clay Cather is an academic researcher from Baylor University Medical Center. The author has contributed to research in topics: Psoriasis & Medicine. The author has an hindex of 22, co-authored 65 publications receiving 2311 citations. Previous affiliations of Jennifer Clay Cather include University of Texas at Austin & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt,Marjolein S. de Bruin-Weller,Melinda Gooderham,Jennifer Clay Cather,Jamie Weisman,David M. Pariser,Eric L. Simpson,Kim A. Papp,H. Chih ho Hong,Diana Rubel,Peter Foley,Errol P. Prens,Christopher E.M. Griffiths,Takafumi Etoh,Pedro Herranz Pinto,Ramon M. Pujol,Jacek C Szepietowski,Karel Ettler,Lajos Kemény,Xiaoping Zhu,Bolanle Akinlade,Thomas Hultsch,Vera Mastey,Abhijit Gadkari,Laurent Eckert,Nikhil Amin,Neil M.H. Graham,Gianluca Pirozzi,Neil Stahl,George D. Yancopoulos,Brad Shumel +30 more
TL;DR: This 1-year, randomised, double-blinded, placebo-controlled, phase 3 study aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical cortiosteroids in adults with moderate-to-severe atopic dermatitis.
Journal ArticleDOI
Association of Erythrodermic Cutaneous T-Cell Lymphoma, Superantigen-Positive Staphylococcus aureus, and Oligoclonal T-Cell Receptor Vβ Gene Expansion
Clotilde M. Jackow,Jennifer Clay Cather,Vicki Hearne,Arisa T. Asano,James M. Musser,Madeleine Duvic +5 more
TL;DR: These studies show that S aureus containing superantigen enterotoxins are commonly found in patients with CTCL, especially individuals with erythroderma where they could exacerbate and/or perpetuate stimulate chronic T-cell expansion and cutaneous inflammation.
Journal ArticleDOI
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim A. Papp,Jennifer Clay Cather,Les Rosoph,Howard Sofen,Richard G. Langley,Robert Matheson,C. Hu,Robert M. Day +7 more
TL;DR: Apremilast, given orally at 20 or 30 mg twice daily, seems to be efficacious, safe, and tolerable for patients with moderate to severe plaque psoriasis, and these results support continuing, longer-term studies.
Journal ArticleDOI
Etanercept: An overview
Ben Goffe,Jennifer Clay Cather +1 more
TL;DR: The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Journal ArticleDOI
AJC Editor's Consensus: Psoriasis and Coronary Artery Disease
Vincent E. Friedewald,Jennifer Clay Cather,Joel M. Gelfand,Kenneth B. Gordon,Gary H. Gibbons,Scott M. Grundy,Michael Jarratt,James G. Krueger,Paul M. Ridker,Neil J. Stone,William C. Roberts +10 more
TL;DR: This research examines the role of biomarkers in the detection and treatment of cardiovascular disease and their role in the development and use in the management of inflammatory biomarkers.